IL231226A - Compounds and preparations as kinase c-kit inhibitors, pharmaceutical preparations containing them and their use in the preparation of medicines for the treatment of diseases - Google Patents

Compounds and preparations as kinase c-kit inhibitors, pharmaceutical preparations containing them and their use in the preparation of medicines for the treatment of diseases

Info

Publication number
IL231226A
IL231226A IL231226A IL23122614A IL231226A IL 231226 A IL231226 A IL 231226A IL 231226 A IL231226 A IL 231226A IL 23122614 A IL23122614 A IL 23122614A IL 231226 A IL231226 A IL 231226A
Authority
IL
Israel
Prior art keywords
compositions
medicaments
compounds
preparation
kinase inhibitors
Prior art date
Application number
IL231226A
Other languages
English (en)
Hebrew (he)
Other versions
IL231226A0 (en
Original Assignee
Novartis Ag
Novartis Int Pharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Int Pharmaceutical Ltd filed Critical Novartis Ag
Publication of IL231226A0 publication Critical patent/IL231226A0/en
Publication of IL231226A publication Critical patent/IL231226A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL231226A 2011-09-01 2014-02-27 Compounds and preparations as kinase c-kit inhibitors, pharmaceutical preparations containing them and their use in the preparation of medicines for the treatment of diseases IL231226A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161530028P 2011-09-01 2011-09-01
PCT/US2012/052621 WO2013033070A1 (en) 2011-09-01 2012-08-28 COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS

Publications (2)

Publication Number Publication Date
IL231226A0 IL231226A0 (en) 2014-04-30
IL231226A true IL231226A (en) 2017-03-30

Family

ID=46829898

Family Applications (1)

Application Number Title Priority Date Filing Date
IL231226A IL231226A (en) 2011-09-01 2014-02-27 Compounds and preparations as kinase c-kit inhibitors, pharmaceutical preparations containing them and their use in the preparation of medicines for the treatment of diseases

Country Status (42)

Country Link
US (1) US9199981B2 (enExample)
EP (1) EP2751102B1 (enExample)
JP (1) JP6117208B2 (enExample)
KR (1) KR101959590B1 (enExample)
CN (1) CN103764653B (enExample)
AP (1) AP2014007494A0 (enExample)
AR (1) AR087752A1 (enExample)
AU (1) AU2012300248B2 (enExample)
BR (1) BR112014004504B1 (enExample)
CA (1) CA2845159C (enExample)
CL (1) CL2014000494A1 (enExample)
CO (1) CO6900140A2 (enExample)
CR (1) CR20140106A (enExample)
CU (1) CU20140023A7 (enExample)
CY (1) CY1121695T1 (enExample)
DK (1) DK2751102T3 (enExample)
EA (1) EA024293B1 (enExample)
ES (1) ES2732671T3 (enExample)
GT (1) GT201400036A (enExample)
HR (1) HRP20191140T1 (enExample)
HU (1) HUE044373T2 (enExample)
IL (1) IL231226A (enExample)
JO (1) JOP20120246B1 (enExample)
LT (1) LT2751102T (enExample)
MA (1) MA35459B1 (enExample)
ME (1) ME03395B (enExample)
MX (1) MX342329B (enExample)
MY (1) MY167245A (enExample)
PE (1) PE20141033A1 (enExample)
PH (1) PH12014500351B1 (enExample)
PL (1) PL2751102T3 (enExample)
PT (1) PT2751102T (enExample)
RS (1) RS59025B1 (enExample)
SG (1) SG2014011050A (enExample)
SI (1) SI2751102T1 (enExample)
TN (1) TN2014000061A1 (enExample)
TR (1) TR201909189T4 (enExample)
TW (1) TWI543981B (enExample)
UA (1) UA110841C2 (enExample)
UY (1) UY34300A (enExample)
WO (1) WO2013033070A1 (enExample)
ZA (1) ZA201401113B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569283B2 (en) 2011-09-01 2013-10-29 Valentina Molteni Compounds and compositions as c-Kit kinase inhibitors
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
ES2689429T3 (es) * 2012-07-13 2018-11-14 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de actividad de TNF
WO2014110200A1 (en) 2013-01-10 2014-07-17 Zisman Lawrence S Non-selective kinase inhibitors
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
ES2959419T3 (es) 2013-10-11 2024-02-26 Pulmokine Inc Formulaciones secas por aspersión
WO2015082411A1 (de) * 2013-12-05 2015-06-11 Bayer Pharma Aktiengesellschaft Aryl- und hetaryl-substituierte imidazo[1,2-a]pyridin-3-carboxamide und ihre verwendung
CN103965190A (zh) * 2014-05-20 2014-08-06 定陶县友帮化工有限公司 一种咪唑并[1,2-a]吡啶-3-甲酸的合成方法
MD3316969T2 (ro) 2015-07-02 2022-07-31 Janssen Sciences Ireland Unlimited Co Compuși antibacterieni
US10059708B2 (en) * 2016-04-26 2018-08-28 Northwestern University Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
MA45377A (fr) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Co Composés hétérocycliques en tant qu'agents antibacteriens
EP3472152A1 (en) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacte rials
RU2763525C2 (ru) 2016-10-27 2021-12-30 Пульмокин, Инк. Комбинированная терапия для лечения легочной гипертензии
MA47676A (fr) 2017-03-01 2021-06-02 Janssen Sciences Ireland Unlimited Co Polythérapie
CN111039946A (zh) * 2018-10-15 2020-04-21 上海轶诺药业有限公司 一类咪唑并芳环类化合物的制备和应用
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
TW202108581A (zh) * 2019-05-13 2021-03-01 瑞士商諾華公司 N-(5-(5-((1r,2s)-2氟環丙基)-1,2,4-㗁二唑-3-基)-2-甲基苯基)咪唑并[1,2-a]吡啶-3-甲醯胺之結晶型
CN114423758B (zh) 2019-09-13 2025-05-27 爱尔兰詹森科学公司 抗细菌化合物
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US12624011B2 (en) * 2020-03-17 2026-05-12 Sumitomo Pharma Co., Ltd. Oxadiazole derivative
JP2023534963A (ja) 2020-07-15 2023-08-15 サード ハーモニック バイオ, インコーポレイテッド 選択的c-kitキナーゼ阻害剤の結晶質形態
TW202237096A (zh) 2020-11-19 2022-10-01 瑞士商諾華公司 選擇性c-kit激酶抑制劑之醫藥組合物及其製造及使用方法
TW202237097A (zh) * 2020-11-19 2022-10-01 美商第三諧波生物公司 選擇性c-kit激酶抑制劑之醫藥組合物及其製造及使用方法
WO2022182982A1 (en) * 2021-02-26 2022-09-01 Third Harmonic Bio, Inc. Methods for treating c-kit kinase mediated diseases and disorders using a selective c-kit kinase inhibitor
WO2022194803A1 (en) 2021-03-16 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
MX2023010941A (es) 2021-03-17 2023-11-28 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
CA3211592A1 (en) 2021-03-17 2022-09-22 Jerome Emile Georges Guillemont Antibacterial compounds
CA3234515A1 (en) 2021-10-28 2023-05-04 Jose Manuel Bartolome-Nebreda Imidazopyridine amides and related compounds for use in the treatment of bacterial infections
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
EP4626884A1 (en) 2022-11-30 2025-10-08 Blueprint Medicines Corporation N-phenyl-pyrazolo[1,5-a]pyridine-3-carboxamide derivatives as wild type c-kit kinase inhibitors for the treatment of urticaria
EP4630423A1 (en) * 2022-12-07 2025-10-15 Third Harmonic Bio, Inc. Compounds and compositions as c-kit kinase inhibitors
WO2024124002A1 (en) * 2022-12-07 2024-06-13 Third Harmonic Bio, Inc. Compounds and compositions as c-kit kinase inhibitors
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
US20250042898A1 (en) * 2023-07-25 2025-02-06 Enanta Pharmaceuticals, Inc. Pharmaceutical Compounds And Compositions As c-Kit Kinase Inhibitors
US12384773B2 (en) 2023-11-02 2025-08-12 Arcus Biosciences, Inc. Thiazole compounds and methods of use thereof
CN122580315A (zh) * 2024-01-04 2026-08-14 上海翰森生物医药科技有限公司 多环类衍生物抑制剂、其制备方法和应用
TW202613113A (zh) * 2024-06-11 2026-04-01 大陸商上海翰森生物醫藥科技有限公司 吡唑類衍生物抑制劑、其製備方法和應用
WO2025259929A1 (en) * 2024-06-13 2025-12-18 Third Harmonic Bio, Inc. COMPOUNDS AND COMPOSITIONS AS c-Kit KINASE INHIBITORS
WO2025256609A1 (en) * 2024-06-13 2025-12-18 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
WO2025261494A1 (zh) * 2024-06-21 2025-12-26 上海美悦生物科技发展有限公司 一种稠杂环化合物、其制备方法和用途
WO2026026755A1 (zh) * 2024-07-30 2026-02-05 上海美悦生物科技发展有限公司 一种杂环化合物、其制备方法和用途
WO2026032333A1 (zh) * 2024-08-06 2026-02-12 上海美悦生物科技发展有限公司 一种杂环化合物、其制备方法和用途
WO2026037418A1 (zh) * 2024-08-16 2026-02-19 上海美悦生物科技发展有限公司 一种杂环化合物、其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518993D0 (en) * 1995-09-16 1995-11-15 Agrevo Uk Ltd Fungicides
US20070072861A1 (en) * 2000-03-27 2007-03-29 Barbara Roniker Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2004001903A2 (en) 2002-06-20 2003-12-31 Beacon Looms, Inc. Knitted electrical conductor fabric
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
EA200970447A1 (ru) * 2006-11-03 2009-10-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
SG10202010119TA (en) * 2010-11-15 2020-11-27 Abbvie Inc NAMPT And Rock Inhibitors
CA2845785A1 (en) * 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as c-kit kinase inhibitors
CN103930424A (zh) * 2011-09-01 2014-07-16 Irm责任有限公司 作为c-Kit激酶抑制剂的化合物和组合物
US8569283B2 (en) * 2011-09-01 2013-10-29 Valentina Molteni Compounds and compositions as c-Kit kinase inhibitors

Also Published As

Publication number Publication date
GT201400036A (es) 2015-06-02
RS59025B1 (sr) 2019-08-30
KR20140071382A (ko) 2014-06-11
TN2014000061A1 (en) 2015-07-01
JP6117208B2 (ja) 2017-04-19
LT2751102T (lt) 2019-07-10
BR112014004504A2 (pt) 2017-03-28
ES2732671T3 (es) 2019-11-25
KR101959590B1 (ko) 2019-03-18
SG2014011050A (en) 2014-08-28
WO2013033070A1 (en) 2013-03-07
HRP20191140T1 (hr) 2019-09-20
JP2014525444A (ja) 2014-09-29
SI2751102T1 (sl) 2019-08-30
AR087752A1 (es) 2014-04-16
PL2751102T3 (pl) 2019-09-30
CO6900140A2 (es) 2014-03-20
ZA201401113B (en) 2015-10-28
CL2014000494A1 (es) 2014-09-05
DK2751102T3 (da) 2019-07-01
EA201490540A1 (ru) 2014-06-30
BR112014004504B1 (pt) 2022-03-22
PT2751102T (pt) 2019-07-10
PH12014500351B1 (en) 2019-04-03
AU2012300248B2 (en) 2015-08-27
MX342329B (es) 2016-09-26
US20130059846A1 (en) 2013-03-07
TWI543981B (zh) 2016-08-01
NZ621092A (en) 2016-06-24
MA35459B1 (fr) 2014-09-01
US9199981B2 (en) 2015-12-01
CR20140106A (es) 2014-05-02
CN103764653B (zh) 2015-12-02
TR201909189T4 (tr) 2019-07-22
CN103764653A (zh) 2014-04-30
JOP20120246B1 (ar) 2022-03-14
PE20141033A1 (es) 2014-08-30
HUE044373T2 (hu) 2019-10-28
ME03395B (me) 2020-01-20
MY167245A (en) 2018-08-14
TW201313716A (zh) 2013-04-01
CU20140023A7 (es) 2014-04-24
UA110841C2 (uk) 2016-02-25
CA2845159C (en) 2020-11-03
CY1121695T1 (el) 2020-07-31
UY34300A (es) 2013-04-05
CA2845159A1 (en) 2013-03-07
EP2751102B1 (en) 2019-03-27
AP2014007494A0 (en) 2014-03-31
AU2012300248A1 (en) 2014-04-17
PH12014500351A1 (en) 2014-04-07
EA024293B1 (ru) 2016-09-30
MX2014002482A (es) 2014-11-25
IL231226A0 (en) 2014-04-30
EP2751102A1 (en) 2014-07-09

Similar Documents

Publication Publication Date Title
IL230874A (en) History of dihydroquinoline-2-on-egg scallops, their preparation process, pharmaceutical preparations containing them and their use in the preparation of drugs
IL232308A (en) Compounds as modulators of atp-linked casting, pharmaceuticals containing them and their use in the preparation of drugs for the treatment of diseases and processes for their preparation
AP3847A (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
IL236221A (en) History of theophyridone and pharmacological preparations containing them for the treatment of diseases
IL250740A0 (en) Piperazine-2,5-dione derivatives, pharmaceutical preparations containing them and their use for the preparation of medicines
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
IL223795A (en) History of Tetrahydro-Pyrido-Pyrimidine
MX349004B (es) Nuevos compuestos.
IL227594A (en) History of Aminobutyric Replaced as Nephrilicin Inhibitors, their Preparation, Pharmaceutical Preparations Containing Them and Their Use in Medication Preparation
IL222120A (en) Annals (indole-1-yl) -carbonylalkyl, process for preparation, pharmaceutical preparations containing them and their use in the preparation of cancer drugs
PL2807159T3 (pl) Nowe pochodne indolizyny, sposób ich wytwarzania i kompozycje farmaceutyczne je zawierające do leczenia raka
PL3444261T3 (pl) Pochodne 2,2-difluoropropionamidowe bardoksolonu metylu, ich kompozycje farmaceutyczne i formy polimorficzne do zastosowania w leczeniu określonych stanów
IL221556A (en) Kinase inhibitors and their use in cancer drug preparation
IL235923A0 (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical preparations thereof
IL231270A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceuticals containing them and methods of use
IL232701A (en) Pirazine compounds that inhibit sick kinase, pharmaceutical preparations that contain them and their use in the preparation of drugs
SG10201709133QA (en) Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
IL232035A (en) These heterocyclic compounds, these compounds as a medicine and a pharmaceutical composition containing them
IL223872A (en) Pyrazoloquinoline derivatives and intermediates, process for preparation, use and pharmaceutical preparations and preparations containing them
IL229005A (en) Pyrazolidine-3-derivatives, their process, their preparations and their use in the preparation of schizophrenia and cognitive diseases
IL227024A (en) The 3 heteroarylamino propionic acid derivatives are converted into amino acids, a process for their preparation, their use in the preparation of medicinal preparations and as medical preparations containing them
ZA201306905B (en) Novel octahydrothienoquinonline derivative,pharmaceutical composition comprising derivative, and use of these
IL225105A (en) Heterocyclic compounds, their process, their pharmaceutical preparations and their use in the preparation of drugs
EP2701689A4 (en) PHARMACEUTICAL COMPOSITIONS OF RALTEEGRAVIR, METHODS OF PREPARATION AND USE THEREOF
SI2662382T1 (sl) Sterolni derivativi, njihova priprava, farmacevtske sestave, ki jih vsebujejo, in njihova uporaba za zdravljenje več glioblastomov

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed